Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt FR0010397232

Laatste koers (eur) Verschil Volume
0,459   -0,006   (-1,29%) Dagrange 0,456 - 0,469 111.132   Gem. (3M) 239,1K

Novacyt de volgende biotech raket!

Volgen
70.928 Posts
Pagina: «« 1 ... 3542 3543 3544 3545 3546 3547 | Laatste | Omlaag ↓
  4. Eljee66 25 maart 2025 17:19
    Dit was dus de reden



    Paris, France, and Manchester, UK – 18 March 2025 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update further to the Health and Safety Executive (“HSE”) Prosecution announcement made on 21 January 2025 (RNS: 1680U).



    Lab21 Healthcare Ltd (“Lab 21”), a non-trading subsidiary of Novacyt, has pleaded guilty at Exeter Magistrates Court today to health and safety charges relating to the historical operation of its site in Axminster, Devon between 28 June 2018 and 5 April 2019.



    The Company has co-operated with the HSE throughout the investigation and the Lab 21 operations no longer form any part of the Novacyt’s ongoing business. The lease for the site was originally taken over as part of an acquisition announced on 28 June 2018.



    The sentencing hearing is currently planned to be held on the 11 September 2025 to determine the applicable penalty. A further announcement will be made following the outcome.
  5. forum rang 4 High Finance 25 maart 2025 22:51
    quote:

    Eljee66 schreef op 25 maart 2025 17:19:

    Dit was dus de reden



    Paris, France, and Manchester, UK – 18 March 2025 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update further to the Health and Safety Executive (“HSE”) Prosecution announcement made on 21 January 2025 (RNS: 1680U).



    Lab21 Healthcare Ltd (“Lab 21”), a non-trading subsidiary of Novacyt, has pleaded guilty at Exeter Magistrates Court today to health and safety charges relating to the historical operation of its site in Axminster, Devon between 28 June 2018 and 5 April 2019.



    The Company has co-operated with the HSE throughout the investigation and the Lab 21 operations no longer form any part of the Novacyt’s ongoing business. The lease for the site was originally taken over as part of an acquisition announced on 28 June 2018.



    The sentencing hearing is currently planned to be held on the 11 September 2025 to determine the applicable penalty. A further announcement will be made following the outcome.
    Verwachte boete minder dan 50k pond.
    Lijkt me geen reden voor een 15% koersdaling.
70.928 Posts
Pagina: «« 1 ... 3542 3543 3544 3545 3546 3547 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee